InvestorWire NewsRoom

InvestorNewsBreak

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Granted Extension to Regain Compliance with Nasdaq Listing Requirements
July 2, 2024

InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Granted Extension to Regain Compliance with Nasdaq Listing Requirements

180 Life Sciences (NASDAQ: ATNF) today announced its receipt of notice from the Nasdaq Listing Qualifications Panel of the Nasdaq Stock Market LLC that the panel has determined to grant the company’s request to continue its listing on the Nasdaq Stock Market. The continued listing is subject to the company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by 180 Life Sciences to achieve compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Equity Rule (defined in the announcement) and providing an indication of its equity following those transactions. “We believe the extension granted by the Nasdaq Hearings Panel will allow us to finish executing on our plan to regain compliance with Nasdaq’s minimum stockholders’ equity requirement,” said Blair Jordan, interim CEO of 180 Life Sciences.

To view the full press release, visit https://ibn.fm/9imi4

About 180 Life Sciences Corp.

180 Life Sciences is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).